{"id":1219,"date":"2002-08-01T12:03:00","date_gmt":"2002-08-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/aspirin-resistenz"},"modified":"2002-08-01T12:03:00","modified_gmt":"2002-08-01T10:03:00","slug":"aspirin-resistenz","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/aspirin-resistenz","title":{"rendered":"&#8222;Aspirin-Resistenz&#8220;"},"content":{"rendered":"<p>Niedrig dosierte Azetylsalizyls\u00e4ure (ASS) inaktiviert zu \u00fcber 95% das Enzym Zyklooxygenase (COX-1-Isoform). In den kernlosen Thrombozyten ist diese COX-1-Hemmung irreveriblel. Als Folge wird u.a. die Thromboxan-A2-Synthese vermindert und die Aggregationsf\u00e4higkeit der Thrombozyten um 80% reduziert. In zahllosen Studien konnte nachgewiesen werden, da\u00df diese Thrombozytenfunktionshemmung durch ASS einen gro\u00dfen Nutzen in Therapie und Sekund\u00e4rprophylaxe kardiovaskul\u00e4rer Erkrankungen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Niedrig dosierte Azetylsalizyls\u00e4ure (ASS) inaktiviert zu \u00fcber 95% das Enzym Zyklooxygenase (COX-1-Isoform). In den kernlosen Thrombozyten ist diese COX-1-Hemmung irreveriblel. Als Folge wird u.a. die Thromboxan-A2-Synthese vermindert und die Aggregationsf\u00e4higkeit der Thrombozyten um 80% reduziert. In zahllosen Studien konnte nachgewiesen werden, da\u00df diese Thrombozytenfunktionshemmung durch ASS einen gro\u00dfen Nutzen in Therapie und Sekund\u00e4rprophylaxe kardiovaskul\u00e4rer Erkrankungen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,2686,77,76,1677],"class_list":["post-1219","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-aspirin-resistenz","tag-ass","tag-azetylsalizylsaeure","tag-hope-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1219"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1219\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}